Rapid effects of S-ketamine on the morphology of hippocampal astrocytes and BDNF serum levels in a sex-dependent manner.
Antidepressant
Astrocyte
BDNF
Hippocampus
Ketamine
Journal
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
ISSN: 1873-7862
Titre abrégé: Eur Neuropsychopharmacol
Pays: Netherlands
ID NLM: 9111390
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
10
06
2019
revised:
13
12
2019
accepted:
02
01
2020
pubmed:
25
1
2020
medline:
11
8
2021
entrez:
25
1
2020
Statut:
ppublish
Résumé
The prevalence of major depressive disorder (MDD) is higher in women than men. Importantly, a differential behavioral response by sex to the antidepressant response to ketamine in rodents has been reported. Mechanistically, male depressed-like animals showed an increased spine density after ketamine treatment via restoration of synaptic protein levels while those proteins were not altered in female rats. In addition, preclinical studies indicate that the impairment of astrocytic plasticity is one of the contributing mechanisms in the pathophysiology of MDD. Accordingly, in this study, we determined the effect of sex on the rapid morphological alteration of hippocampal astrocytes and the serum level of BDNF one hour after S-ketamine injection. A single intraperitoneal dose of S-ketamine (15 mg/kg) or saline was injected to the male and female Flinders Sensitive Line (FSL) rats, a genetic animal model of depression and their brains were perfused one hour after treatment. The size of the GFAP positive astrocytes in the hippocampal subregions was measured. The volume of different hippocampal subregions was assessed using the Cavalieri estimator. Moreover, serum levels of BDNF were measured with enzyme-linked immunosorbent assay (ELISA) kits. The volume of hippocampal subregions significantly increased one hour after S-ketamine in both male and female FSL animals. However, a substantial alteration in the morphology of the hippocampal astrocytes was observed only in the female rats. Additionally, significantly increased serum BDNF levels in the female depressed rats were observed one hour after S-ketamine treatment. Our results indicate that the rapid effects of S-ketamine on the morphology of the hippocampal astrocytes and the serum level of BDNF are sex-dependent.
Identifiants
pubmed: 31973999
pii: S0924-977X(20)30003-1
doi: 10.1016/j.euroneuro.2020.01.001
pmc: PMC7281850
mid: NIHMS1595010
pii:
doi:
Substances chimiques
Bdnf protein, rat
0
Biomarkers
0
Brain-Derived Neurotrophic Factor
0
Esketamine
50LFG02TXD
Ketamine
690G0D6V8H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
94-103Subventions
Organisme : Intramural NIH HHS
ID : ZIA MH002857
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. and ECNP. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest All authors declare that they have no conflicts of interest.
Références
J Neurobiol. 2005 Jul;64(1):34-46
pubmed: 15884004
J Psychiatr Res. 2013 Jul;47(7):892-9
pubmed: 23548331
Neuroscience. 2019 Feb 1;398:182-192
pubmed: 30537521
Neuroscience. 2015 Apr 2;290:49-60
pubmed: 25595985
Curr Neuropharmacol. 2017;15(1):57-70
pubmed: 26997505
Cell Mol Neurobiol. 2012 Aug;32(6):953-6
pubmed: 22450870
Mech Dev. 2001 Oct;108(1-2):45-57
pubmed: 11578860
Arch Gen Psychiatry. 2005 Jun;62(6):593-602
pubmed: 15939837
Brain Res Mol Brain Res. 2005 Jul 29;138(1):1-7
pubmed: 15896872
Br J Pharmacol. 2017 Mar;174(6):483-492
pubmed: 28087979
Mol Psychiatry. 2018 Apr;23(4):801-811
pubmed: 29532791
Curr Drug Targets. 2013 Oct;14(11):1225-36
pubmed: 23469922
Int Rev Cytol. 2000;197:203-77
pubmed: 10761118
Brain Res Dev Brain Res. 2001 Nov 26;131(1-2):149-52
pubmed: 11718845
Biol Psychiatry. 2013 Aug 15;74(4):250-6
pubmed: 22840761
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813226
J Clin Pharm Ther. 2015 Apr;40(2):125-30
pubmed: 25545040
Int J Neuropsychopharmacol. 2017 Mar 1;20(3):247-256
pubmed: 27815416
Prog Brain Res. 2007;163:3-22
pubmed: 17765709
Acta Neuropsychiatr. 2019 Oct;31(5):258-265
pubmed: 31230597
Annu Rev Psychol. 2010;61:111-40, C1-3
pubmed: 19575621
Biol Psychiatry. 2004 Nov 1;56(9):640-50
pubmed: 15522247
Expert Rev Clin Pharmacol. 2017 Feb;10(2):153-166
pubmed: 27781556
Behav Brain Res. 2016 Oct 1;312:305-12
pubmed: 27343934
Cereb Cortex. 2002 Apr;12(4):386-94
pubmed: 11884354
Neural Plast. 2017;2017:4605971
pubmed: 28491480
Nature. 2016 May 04;533(7604):481-6
pubmed: 27144355
J Comp Neurol. 2003 Oct 27;465(4):540-50
pubmed: 12975814
Biol Psychiatry. 2012 Jun 1;71(11):996-1005
pubmed: 22036038
Nature. 2011 Jun 15;475(7354):91-5
pubmed: 21677641
Neuroscience. 2016 Aug 4;329:337-48
pubmed: 27210075
J Neurosci. 2001 Jan 15;21(2):581-9
pubmed: 11160437
Psychopharmacology (Berl). 2016 Jul;233(14):2813-25
pubmed: 27236785
J Pharmacol Exp Ther. 2018 Dec;367(3):393-404
pubmed: 30213876
Neuropharmacology. 2013 Jul;70:27-34
pubmed: 23337256
Int J Neuropsychopharmacol. 2014 Oct 31;18(1):
pubmed: 25539510
Acta Neuropsychiatr. 2020 Feb;32(1):1-9
pubmed: 31186075
Biol Psychiatry. 1999 May 1;45(9):1085-98
pubmed: 10331101
Expert Rev Neurother. 2012 Oct;12(10):1169-72
pubmed: 23082730
Mol Neurobiol. 2019 Nov;56(11):7368-7379
pubmed: 31037646
J Psychiatr Res. 2000 Nov-Dec;34(6):405-12
pubmed: 11165308
JAMA Psychiatry. 2017 Apr 1;74(4):399-405
pubmed: 28249076
Acta Neuropsychiatr. 2015 Apr;27(2):90-6
pubmed: 25491110
Am J Psychiatry. 2013 Oct;170(10):1134-42
pubmed: 23982301
Biol Psychiatry. 2006 Dec 1;60(11):1206-14
pubmed: 16650831
J Microsc. 1988 Jul;151(Pt 1):3-21
pubmed: 3193456
APMIS. 1988 Oct;96(10):857-81
pubmed: 3056461
CNS Neurol Disord Drug Targets. 2007 Jun;6(3):219-33
pubmed: 17511618